Impact of Subsequent Therapies on Outcome of the FIRE-3/AIO KRK0306 Trial: First-Line Therapy With FOLFIRI Plus Cetuximab or Bevacizumab in Patients With KRAS Wild-Type Tumors in Metastatic Colorectal Cancer [Gastrointestinal Cancer]

Conclusion
Our data suggest that the sequence of drug application might be more important than exposure to single agents. In patients with RAS wild-type tumors, first-line application of anti–epidermal growth factor receptor–directed therapy may represent a favorable condition for promoting effective subsequent therapy including antiangiogenic agents.

Source: Journal of Clinical Oncology - November 6, 2015 Category: Cancer & Oncology Authors: Modest, Stintzing, von Weikersthal, Decker, Kiani, Vehling-Kaiser, Al-Batran, Heintges, Lerchenmuller, Kahl, Seipelt, Kullmann, Stauch, Scheithauer, Held, Mohler, Jung, Kirchner, Heinemann Tags: Chemotherapy, Combined Modality, Translational Oncology Gastrointestinal Cancer Source Type: research